| Literature DB >> 27869211 |
Jiaokun Jia1,2,3,4, Anxin Wang1,2,3,4,5, Jing Wang1,2,3,4, Jianwei Wu1,2,3,4, Xiujuan Yan1,2,3,4, Yong Zhou6, Shengyun Chen1,2,3,4, Xingquan Zhao1,2,3,4.
Abstract
Little is known about the association between homocysteine (Hcy) and asymptomatic CAS in the healthy population. The purpose of this study was to investigate the relationship between Hcy levels and asymptomatic CAS in a Chinese community population. The current study included 5393 participants who were age of 40 years or older, and free of stroke, transient ischemic attack, and coronary artery disease. Demographic and clinical variables were investigated, and the presence of CAS was assessed by Color Doppler Ultrasound. A multivariate logistic regression was used to examine the association between Hcy levels and asymptomatic CAS. 361 (6.69%) participants were diagnosed with asymptomatic CAS, who had higher Hcy levels compared with those without (p-value for trend = 0.0001). After adjusting other possible risk factors, Hcy > 19.3μmol/L was considered as an independent indicator of asymptomatic CAS (OR 1.53, 95%CI 1.05-2.23; p-value for trend = 0.0265), but with a difference between participants with diabetes and without [OR (95%CI): 2.89(1.02-8.22) vs. 1.42(0.95-2.12); P interaction < 0.05]. In this large-population, community-based study, Hcy is an independent indicator of asymptomatic CAS, especially in patients with diabetes.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27869211 PMCID: PMC5116757 DOI: 10.1038/srep37361
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline demographic characteristics and cardiovascular risk factors between groups with/without asymptomatic carotid stenosis.
| Without Asymptomatic CAS (n = 5032) | With Asymptomatic CAS (n = 361) | ||
|---|---|---|---|
| 52.32(45.64–60.90) | 57.02(46.20–74.05) | <0.0001 | |
| 4962 (98.6%) | 354(98.1%) | 0.3575 | |
| Gender n(%) | <0.0001 | ||
| Male | 2924(58.1%) | 302(83.7%) | |
| Female | 2108(41.9%) | 59(16.3%) | |
| 1548(30.76%) | 169(47.0%) | <0.001 | |
| 2395(47.6%) | 196(54.3%) | 0.0142 | |
| 589 (11.7%) | 58(16.1%) | 0.0185 | |
| 2330(46.3%) | 156(43.2%) | 0.2744 | |
| 957(19.0%) | 90(24.9%) | 0.0061 | |
| 69(1.4%) | 6(1.7%) | 0.6485 | |
| 293(5.8%) | 32(8.9%) | 0.0190 | |
| 69(1.4%) | 9/361 (2.5%) | 0.1038 | |
| 24.77(22.76–27.05) | 24.09(21.97–26.57) | <0.0001 | |
| <25 n(%) | 2656 (52.8%) | 228 (63.2%) | 0.0003 |
| 25–30 n(%) | 2041 (40.6%) | 120 (33.2%) | |
| >30 n(%) | 335 (6.7%) | 13 (3.6%) | |
| 1.0(0.5–2.14) | 1.1(0.6–2.95) | 0.0054 | |
| 13.4(9.5–19.0) | 16.3(11.9–22.8) | <0.0001 | |
| 1st tile(<9.6) n(%) | 1316 (26.2%) | 50 (12.9%) | <0.0001 |
| 2st tile(9.6~13.6) n(%) | 1257 (25.0%) | 76 (21.1%) | |
| 3st tile(13.6~19.3) n(%) | 1256 (25.0%) | 92 (25.6%) | |
| 4st tile(>19.3) n(%) | 1203 (23.9%) | 143 (39.6%) |
Values are median (interquartile range) or number (percent).CAS: carotid stenosis; BMI: body mass index; hs-CRP: high-sensitivity C reactive protein; Hcy: homocysteine.
Figure 1Prevalence of asymptomatic carotid stenosis(CAS) stratified by quartile of homocysteine.
Multivariate-adjusted OR and 95% CI for asymptomatic carotid stenosis.
| Quartile of homocysteine (μmol/L) | p-value for trend | ||||
|---|---|---|---|---|---|
| 1st tile(<9.6) | 2st tile(9.6 ~ 13.6) | 3st tile(13.6 ~ 19.3) | 4st tile(>19.3) | ||
| <0.001 | |||||
| OR(95%CI) | 1.00 (Reference) | 1.66(1.14–2.40) | 2.03(1.42–2.91) | 3.15(2.25–4.42) | |
| p | 0.008 | <0.001 | <0.001 | ||
| 0.0216 | |||||
| OR(95%CI) | 1.00 (Reference) | 1.22(0.83–1.78) | 1.20(0.82–1.74) | 1.52(1.05–2.19) | |
| p | 0.32 | 0.35 | 0.03 | ||
| 0.0265 | |||||
| OR(95%CI) | 1.00 (Reference) | 1.23(0.84–1.81) | 1.24(0.85–1.81) | 1.53(1.05–2.23) | |
| p | 0.28 | 0.27 | 0.03 | ||
OR: odd ratio; CI: confidence interval.
Model 1: adjusted for age and gender.
Model 2: adjusted for age, gender, BMI, hypertension, diabetes, hyperlipidemia, antihypertensive drugs, lipid-lowering drugs, antidiabetic drugs, current smoking and hs-CRP.
Multivariate-adjusted OR and 95%CI for asymptomatic carotid stenosis according to quartile of homocysteine, stratified by age, gender and selected risk factors.
| Quartile of homocysteine (μmol/L) | Continuous Scale | P interaction | ||||
|---|---|---|---|---|---|---|
| 1st tile(<9.6) | 2st tile(9.6 ~ 13.6) | 3st tile(13.6 ~ 19.3) | 4st tile(>19.3) | |||
| Age | 0.76 | |||||
| <60y | 1 | 1.33(0.85–2.10) | 1.56(0.99–2.46) | 1.60(1.01–2.53)* | 1.01(0.99–1.02) | |
| ≥60y | 1 | 0.98(0.46–2.06) | 0.85(0.41–1.76) | 1.03(0.51–2.10) | 0.99(0.97–1.01) | |
| gender | 0.44 | |||||
| Female | 1 | 1.27(0.68–2.39) | 0.72(0.30–1.70) | 1.71(0.76–3.87) | 1.02(0.98–1.06) | |
| Male | 1 | 1.26(0.77–2.04) | 1.39(0.88–2.22) | 1.60(1.02–2.52)* | 1.00(0.99–1.01) | |
| Hypertension | 0.74 | |||||
| No | 1 | 1.53(0.91–2.57) | 1.36(0.79–2.33) | 2.05(1.22–3.44)* | 1.01(0.99–1.03) | |
| Yes | 1 | 0.97(0.55–1.70) | 1.08(0.63–1.85) | 1.11(0.65–1.91) | 1.00(0.98–1.01) | |
| Diabetes | 0.04 | |||||
| No | 1 | 1.13(0.74–1.71) | 1.30(0.87–1.95) | 1.42(0.95–2.12) | 1.00(0.99–1.01) | |
| Yes | 1 | 2.19(0.77–6.27) | 0.90(0.28–2.86) | 2.89(1.02–8.22)* | 1.02(0.99–1.05) | |
| Hyperlipidemia | 0.59 | |||||
| No | 1 | 1.63(0.97–2.76) | 1.59(0.94–2.68) | 2.16(1.29–3.64)* | 1.01(0.99–1.02) | |
| Yes | 1 | 0.88(0.50–1.53) | 0.90(0.52–1.56) | 1.01(0.59–1.74) | 1.00(0.98–1.02) | |
*P < 0.05.
OR: odd ratio; CI: confidence interval.
Adjusted for age, gender, BMI, hypertension, diabetes, hyperlipidemia, antihypertensive drugs, lipid-lowering drugs, antidiabetic drugs, current smoking and hs-CRP.